ROYALTY PHARMA INCREASES ALL CASH OFFER TO ACQUIRE ELAN TO $12.50 PER SHARE |
|
New York, NY – May 20, 2013 - Following its announces increased offer to $12.50 per share in cash under rule 2.5 of Irish takeover rules. All cash offer is fully financed, cash confirmed and not conditional on due diligence. The increased offer is conditional on Elan Stockholders voting against the Theravance transaction.
|
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING FORMAL CASH OFFER FOR ELAN |
|
New York, NY – May 2, 2013 - Following its announcements on the 15 April and 18 April, Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued an offer document dated 2 May 2013. In the Offer Document, Royalty Pharma confirms the Offer Price set forth in its Rule 2.5 Announcement of 15 April.
|
ROYALTY PHARMA RULE 2.4 RELEASE REGARDING ELAN DUTCH AUCTION RESULT |
|
New York, NY – April 18, 2013 - Consistent with the terms of Royalty Pharma's announcement of a firm intention to make an offer dated 15 April 2013, Royalty Pharma confirms that its Offer Price is US$11.25 per Elan Share and Elan ADS.
|
ROYALTY PHARMA ANNOUNCES FIRM FULLY FINANCED OFFER TO ACQUIRE ELAN |
|
New York, NY – April 15, 2013 - Royalty Pharma announces a firm fully financed cash offer to acquire Elan under rule 2.5 of Irish takeover rules. The Offer is valued at up to US$12 per Elan Share, a 23 percent increase over the enterprise value of Royalty Pharma’s initial February 25, 2013 proposal. The terms of the Offer are determined by the outcome of Elan's recently launched Dutch Auction tender offer.
|
ROYALTY PHARMA STATEMENT REGARDING ELAN PROPOSAL |
|
New York, NY - March 6, 2013 - Royalty Pharma remains committed to acquiring Elan on the terms set out in the Proposal Announcement of February 25, 2013, but continues to be disappointed that the Board of Elan has not engaged in discussions. Royalty Pharma announces today that it is meeting with a number of Elan Shareholders to discuss the Proposal.
|
ROYALTY PHARMA PROPOSAL TO ACQUIRE ELAN CORPORATION, plc |
|
New York, NY – February 25, 2013 - Royalty Pharma is proposing, on an indicative basis, to make an offer for Elan of US$11 for every Elan Share and every Elan ADS. This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules.
|
ROYALTY PHARMA RAISES $600 MILLION OF DEBT |
New York, NY – May 24, 2012 - Royalty Pharma, the industry leader in acquiring royalty interests in
marketed and late stage biopharmaceutical products, announced that it has successfully issued $600
million of incremental Term Loan B debt through RPI Finance Trust (“RPIFT”), bringing total debt
outstanding at RPIFT to approximately $3.4 billion. Proceeds will be used to fund future acquisitions.
|
Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm |
New York, NY – May 2, 2012 - Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).
|
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement |
|
New York, NY and South San Francisco, CA – March 29, 2012 - Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis’ lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
|
Royalty Pharma Acquires Cimzia® and Mircera® Royalties for $124 million |
|
New York, NY – February 29, 2012 - Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million.
|
Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million |
|
San Francisco, CA – February 29, 2012 - Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million.
|
Royalty Pharma Raises $3.6 Billion to Refinance $2.75 Billion of Outstanding Debt and to Fund an $850 Million Cash Distribution to Shareholders |
|
New York, NY - September 07, 2011 - Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.
|
Arisaph Pharmaceuticals and Royalty Pharma Announce Monetization and Amendment of DPP-IV License Agreement |
|
Boston, MA – August 11, 2011 - Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million.
|
Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million |
|
Tokyo - June 30, 2011 - Astellas Pharma Inc. announced today that Prosidion’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of $609 million. The transaction is expected to close in July 2011.
|
Royalty Pharma Announces George Lloyd Joins Management Team |
|
New York, NY - May 18, 2011 - Royalty Pharma is pleased to announce that George Lloyd has joined
the company as Executive Vice President, Investments.
|
Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million |
|
New York, NY - April 4, 2011 - Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.
|
Cypress Bioscience Agrees to be Acquired by Ramius LLC and Royalty Pharma for $6.50 per Share in Cash |
|
San Diego, CA and New York, NY - December 15, 2010 - Cypress Bioscience, Inc. (Nasdaq: CYPB) ("Cypress"), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, announced today that it has entered into a definitive merger agreement with Ramius V&O Acquisition LLC, an affiliate of Ramius LLC (collectively, “Ramius”) and affiliates of Royalty Pharma (“Royalty Pharma”), providing for the acquisition of Cypress by Ramius and Royalty Pharma.
|
Royalty Pharma Announces Alexander von Perfall Joins Management Team |
|
New York, NY - December 7, 2009 - Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.
|
Royalty Pharma Announces James Reddoch, PhD Joins Management Team |
|
New York, NY - July 8, 2008 - Royalty Pharma is pleased to announce that James Reddoch, PhD has joined the company as Executive Vice President, Head of Research.
|
Royalty Pharma Acquires Royalty Interest in RotaTeq® from The Children’s Hospital Foundation for $182 Million |
|
New York, NY - April 23, 2008 - The Children’s Hospital Foundation, the parent company of The Children’s Hospital of Philadelphia® and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq® from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
|
Royalty Pharma Acquires a Portion of Northwestern University’s Royalty Interest in Lyrica® for $700 Million |
|
New York, NY - Dec. 18, 2007 - Royalty Pharma and Northwestern University announced today that Northwestern has sold a portion of its worldwide royalty interest in Lyrica® to Royalty Pharma for $700 million in cash.
|
Royalty Pharma Acquires a Portion of New York University’s Royalty Interest in Remicade® for $650 Million |
|
New York, NY - May 4, 2007 - Royalty Pharma and New York University announced today that NYU has sold a portion of NYU’s worldwide royalty interest in Remicade® to Royalty Pharma.
|
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA® from AstraZeneca and CAT |
|
New York, NY - October 26, 2006 - Royalty Pharma announced today that it has completed the purchase of the rights to a pre-existing royalty interest in HUMIRA® currently held by AstraZeneca plc’s subsidiary, Cambridge Antibody Technology Limited (CAT).
|
Emory Drug Deal Turns Heads |
|
Jumbo $525 Million Royalty Rights Payment Captures Wall Street’s Attention
New York, NY - January 16, 2006 - Wall Street is rubbing its hands in anticipation of more to come after Emory University’s groundbreaking deal to sell the royalty rights for an HIV drug developed by school researchers. Gilead Sciences and Royalty Pharma paid a whopping $525 million for the rights, the largest lump-sum royalty payment to a US university to date.
|
Royalty Pharma Acquires Memorial Sloan-Kettering Cancer Center’s International Royalty Interest in Neupogen® and Neulasta® for $142 Million |
|
New York, NY - August 22, 2005 - Royalty Pharma and Memorial Sloan-Kettering Cancer Center ("MSKCC") announced today that they have completed the sale of a portion of MSKCC’s royalty interest in Neupogen® and Neulasta® worldwide for all countries except the United States, China, Japan, South Korea, North Korea and Taiwan.
|
Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine |
|
Foster City, CA, New York, NY, and Atlanta, GA - July 18, 2005 - Gilead Sciences, Inc (Nasdaq: GILD) and Royalty Pharma today announced that the companies have entered into an agreement with Emory University providing for the purchase of the royalty interest owed to Emory for emtricitabine, also known as Emtriva®. Under the terms of the agreement, Gilead and Royalty Pharma will make a one-time cash payment of $525 million to Emory in exchange for elimination of the emtricitabine royalties due to Emory on worldwide net sales of the product.
|
Ligand, Royalty Pharma Amend SERM Royalty Agreement |
|
Royalty Pharma Accelerates and Increases Royalty Purchase to $32.5 Million as Substitute for Final Two Options
San Diego, CA, and New York, NY - November 9, 2004 - Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing final stages of development, the companies announced today.
|
Royalty Pharma Acquires a Portion of Memorial Sloan-Kettering Cancer Center’s US Royalty Interest in Neupogen/Neulasta |
|
New York, NY - January 22, 2004 - Royalty Pharma acquired a portion of Memorial Sloan-Kettering Cancer Center’s (MSKCC) US royalty interest in Neupogen/Neulasta, the entities announced today. Under the agreement, MSKCC received $263 million in cash up-front plus certain additional payments should Neupogen/Neulasta yearly sales exceed certain agreed sales hurdles. In addition, as part of the agreement, MSKCC has made a $7 million investment in Royalty Pharma.
|
Ligand, Royalty Pharma Amend SERM Royalty Agreement |
|
Royalty Pharma Exercises a $12.5 Million Option on October 1
San Diego, CA, and New York, NY - October 2, 2003 - Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing completion of Phase III development, the companies announced today.
|
Standard & Poors - Royalty Pharma Finance Trust Rating AAA |
Moody's Rates Royalty Pharma Pharmaceutical Royalty Securitization Aaa |
Approximately $225 Million of Asset-Backed Securities Rated Aaa.
New York - July 30, 2003 - Moody's Investors Service has assigned a rating of Aaa to the $225,000,000 asset-backed n
ote issued by Royalty Pharma Finance Trust (RPFT). The notes are backed initially by a pool of royalty interests and
contingent pay rights in thirteen biopharmaceutical products.
This is the first time Moody's has assigned a term rating to a transaction backed by biopharmaceutical royalty interests.
|
Ligand, Royalty Pharma Expand SERM Royalty Agreement, Form New Royalty Partnership for Targretin Capsules |
|
San Diego, CA, and New York, NY (BUSINESS WIRE) - January 6, 2003 - Ligand to use increased proceeds of up to $15.4 million through 2003 to accelerate development of Targretin Capsules in NSCLC monotherapy and Targretin Gel in hand dermatitis
|
Ligand to Receive $3.5 Million as Royalty Pharma Exercises Another Option to Purchase Additional Rights to Future SERM Royalty Streams |
| San Diego, CA - September 18, 2002 |
|
Ligand to Receive $3 Million as Royalty Pharma Exercises First Option to Purchase Additional Rights to Future SERM Royalty Streams |
|
San Diego, CA - April 18, 2002
|
Ligand, Royalty Pharma Conclude Agreement for Rights/Options Tied to Future SERM Royalty Streams |
Payments of up to $56 Million Enable Additional Investments in R&D 2002-2004
San Diego, CA - March 6, 2002 - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today an agreement with Royalty Pharma AG, which has purchased rights to a share of future payments from Ligand’s collaborative partners’ sales of three selective estrogen receptor modulator (SERM) products now in Phase III development.
|
EntreMed Sells Thalidomide Royalty Stream for $24.3 Million |
|
Rockville, MD - August 8, 2001
|
Xoma Receives $17 Million for Anti-CD20 Antibody Patents and Related Rights and $10 Million from Genentech for 1998 hu1124 Program |
|
Berkeley, CA - January 8, 1998
|
|
